• Toremifene Citrate in Breast Cancer: Efficacy, Mechanism, an

  2026-04-25

  This article examines the clinical and mechanistic insights from the reference study on Toremifene Citrate, an oral selective estrogen receptor modulator approved for metastatic breast cancer in postmenopausal women. Key findings include its comparable efficacy to tamoxifen, unique receptor interactions, and specific safety profile, with implications for research on estrogen receptor signaling and hormone receptor modulation.

• Cefepime (BMY-28142): Translational Leverage in CNS Infectio

  2026-04-24

  This article provides mechanistic insight and translational strategy for leveraging Cefepime (BMY-28142) in central nervous system infection research, with evidence-based protocol guidance, context from recent resistance epidemiology, and perspectives for the next wave of antimicrobial innovation. It contextualizes APExBIO's Cefepime product as a research catalyst, offering unique value beyond routine antimicrobial studies.

• Ratiometric Lipid Peroxidation Probes in Translational Resea

  2026-04-24

  This thought-leadership article explores the mechanistic and strategic value of BODIPY 581/591 C11—a ratiometric fluorescent probe—for translational researchers investigating oxidative stress, lipid peroxidation, and ferroptosis. Drawing on new findings in diabetic osteoporosis, the piece provides actionable guidance for leveraging quantitative redox biomarkers to accelerate discovery, benchmark antioxidant interventions, and bridge preclinical findings to clinical relevance, with a focus on rigorous protocol design and evidence integration.

• Protease Inhibitor Cocktails: Safeguarding Translational Pro

  2026-04-23

  This thought-leadership article bridges mechanistic understanding and strategic guidance for translational researchers seeking uncompromised protein integrity in advanced workflows. It highlights the unique challenges of protease inhibition in phosphorylation-sensitive and complex multiprotein applications, contextualizes recent advances in mitochondrial research, and positions APExBIO’s Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) as a keystone solution. Drawing from recent literature and best-practice protocols, it provides actionable recommendations while clarifying the product’s impact beyond conventional use cases.

• Canonical MCL-1 Function Drives Breast Cancer Cell Survival

  2026-04-23

  This paper demonstrates that breast cancer cells depend on the canonical anti-apoptotic function of MCL-1, rather than its non-apoptotic activities. Targeted genetic and pharmacological inhibition of MCL-1 induces apoptosis in tumor models, providing strong evidence for prioritizing MCL-1-specific BH3 mimetics in translational breast cancer research.

• Synthetic Lethality in PPGLs: 131I-MIBG and PARP Inhibitor S

  2026-04-22

  Song et al. (2025) demonstrate a synthetic lethality approach for treating norepinephrine transporter-overexpressing pheochromocytomas and paragangliomas (PPGLs) by combining 131I-MIBG radionuclide therapy with PARP inhibition. Their work reveals a synergistic effect driving enhanced cell cycle arrest and apoptosis in engineered cell models, providing a foundation for future translational strategies.

• Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G: Rel

  2026-04-22

  This article addresses common laboratory challenges in mRNA capping and translation, demonstrating how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G (SKU B8175) delivers reproducible, high-efficiency results. Drawing on quantitative evidence and current protocols, we highlight SKU B8175's role in enhancing mRNA stability, translation, and assay reliability for biomedical researchers and technicians.

• JNK-IN-7: Selective JNK Inhibitor for Apoptosis Pathway Diss

  2026-04-21

  JNK-IN-7, a potent selective JNK inhibitor from APExBIO, enables precise mapping of MAPK-driven apoptosis and immune signaling in cell-based assays. This guide details experimental workflows, troubleshooting, and innovations for dissecting c-Jun phosphorylation and innate immune responses in disease models.

• CHK1 Inhibition in Breast Cancer: Impact of ER/PR Status on

  2026-04-21

  This article examines recent findings on how the effectiveness of CHK1 inhibition in breast cancer is shaped by estrogen and progesterone receptor (ER/PR) status. The study reveals mechanistic differences in chemosensitivity and single-agent antitumor activity, providing a robust framework for rationalizing targeted therapy strategies.

• Distinct Apoptotic Pathways in BMECs Induced by Candida krus

  2026-04-20

  This study elucidates how the yeast and hypha phases of Candida krusei trigger apoptosis in bovine mammary epithelial cells (BMECs) through separate signaling pathways. By differentiating the molecular mechanisms—mitochondrial versus death receptor—the research provides foundational insights for targeted interventions in mycotic mastitis.

• Bedaquiline as a Diarylquinoline Antibiotic: Advanced Workfl

  2026-04-20

  Bedaquiline’s dual action—targeting both Mycobacterium tuberculosis and cancer stem cell metabolism—makes it a critical tool for researchers tackling persistent infections and refractory cancer models. This article delivers evidence-backed protocols, troubleshooting insights, and comparative guidance for maximizing the unique advantages of Bedaquiline (SKU B3492) from APExBIO in both infectious disease and oncology research.

• BODIPY 581/591 C11 for Ferroptosis: Quantitative Lipid Perox

  2026-04-19

  Explore how BODIPY 581/591 C11, a ratiometric fluorescent probe, advances quantitative lipid peroxidation detection in live cells—specifically enabling nuanced ferroptosis and oxidative stress studies in diabetic endothelial models. This article delivers unique insights from recent translational research to inform assay design and interpretation.

• ARCA: Mechanistic Leverage for mRNA Therapeutics Innovation

  2026-04-18

  Explore how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, redefines synthetic mRNA design with mechanistic rigor, enabling translational researchers to unlock new frontiers in mRNA therapeutics. This article blends actionable protocol guidance, experimental validation, and a strategic outlook for those pioneering next-generation RNA medicines.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Protocol and QC Gui

  2026-04-17

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1223) enables sensitive, specific detection of rabbit primary antibodies in ELISA, Western blot, and IHC workflows. This reagent addresses the need for robust signal amplification with minimized background when working with rabbit IgG targets. It is not intended for diagnostic, clinical, or non-immunoassay applications.

• Cisapride (R 51619) in Cardiac Electrophysiology: Applied Wo

  2026-04-16

  Cisapride (R 51619) is a benchmark tool for modeling hERG channel inhibition and 5-HT4 signaling in cardiac electrophysiology research. Recent advances leverage deep learning and iPSC-derived cardiomyocytes, enabling nuanced, high-throughput cardiotoxicity screening and mechanistic insights.

16562 records 1/1105 page Next 12345 下5页 Last page